CSJ148

BIOLOGICAL2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

HCMVHCMV Infection

Phase 2

Efficacy and Safety Study of CSJ148 in Stem Cell Transplant Patients

CompletedNCT02268526

Novartis PharmaceuticalsHCMV

Start: 2015-06-02End: 2016-12-07Updated: 2021-01-05

A Study to Evaluate CSJ148 in Pregnant Women With Primary HCMV Infection

WithdrawnNCT03369912

Novartis PharmaceuticalsHCMV Infection

Start: 2018-10-23End: 2022-11-15Updated: 2018-10-09

Related Papers

Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation.

2020-03-2428 citations